227 hypertensive patients, stage II-III have been investigated using new laboratory technology (patent of Ukraine), to reveal signs of coagulation potential and fibrinolytic tests of whole blood. 120 patients have been observed to detect definite markers of lipid profile. Obtained results revealed depression of fibrinolysis (from I to X degree) in 77.3%, hypercoagulation in 53.3%, and hypocoagulation in 25.6% of patients. These multidirectional changes proves the necessity of a laboratory control during administration of antiplatelets drugs. Besides, having coagulation module (CM) at VI-VIII degree, which corresponds to a high clinical risk factor of and urgent situation, the tactics of the treatment should be aggressive and parenteral. Lipid concentration was considerably higher at hypercoagulation state, although in 11-22% of cases, dislipidemia developed at hypocoagulation state. Total cholesterol (TC) and lipoprotein levels do not influence on formation of blood clot and considerably increase its density (P < 0.01), that complicates dissolving of blood clot by the fibrinolytic system, functional state of which goes down additionally during the increase of TC (r = -0.207; P < 0.05) and LDL (r = -0.197; P < 0.05). Fibrinolytic activity has strongly correlated with clot level (r = -0.465; P < 0.0001) and its density (r = -0.393; P < 0.0001). So, the algorithm of an individual treatment should include antihypertensive (under the control Blood Pressure), antiliplatelets (under the control MC) and hypolipidemic (under the laboratory control) agents.